Meet Our Leadership Team

Our leadership team is tirelessly committed to disrupting cancer’s energy by bringing GP-2250 to market.

Greg Bosch

Chairman & CEO

LinkedIn

Greg Bosch brings over 30 years in healthcare to Panavance with leadership of commercial, operations, and R&D teams in the US and Europe. His general management experience in the life science industry spans the pharmaceutical, biologics and medical device segments including building a biosurgery business to $220M in 5 years, acquiring public and private companies, and taking public a company.  Prior to joining Panavance Greg was Chief Executive Officer of Geistlich Pharma North America where he led a cross functional team to achieve the market leadership position in regenerative medicine in the US dental field. While at Geistlich, he also led the company’s global oncology program and was responsible for the team developing Panavance’s proprietary small molecule drug compound GP-2250 from early R&D through to the clinical studies. Earlier in his career he was the President and Chief Executive Officer of PuriCore PLC where he led a successful IPO on the London Stock Exchange. Prior to his experience with PuriCore he held roles of increasing responsibility at Baxter International including General Manager of the BioSurgery Business, Vice President of Strategic Planning and Assistant to the President. Greg currently serves on the Board of Kibow Biotech, Inc. Greg earned his B.A. in Public Policy from Duke University and MBA from DePaul University.

Greg Bosch Headshot

Greg Bosch

Chairman & CEO

 

José Iglesias, MD

Chief Medical Officer

LinkedIn

Dr. Jose Iglesias is Director of Apex Oncology, a clinical development consultancy focused in the areas of solid tumor oncology, and he is consulting Chief Medical Officer to Panavance Therapeutics. Dr. Iglesias brings 30 years of global experience in the pharmaceutical industry to Panavance, including large pharma and biotech. He has proven leadership in designing and leading all phases of oncology clinical trials, including large Phase 3 registration studies with over 2,000 patients. Since 2019 Dr. Iglesias has been an independent oncology consultant focused in the areas of solid tumor oncology, immuno-oncology and translational medicine, in early phase to mid-phase clinical development. Earlier in his career he held roles of increasing responsibility at Abraxix BioScience including Vice President of Global Clinical Development and Chief Medical Officer where he was responsible for worldwide development of Abraxane and all other pipeline molecules. Dr. Iglesias also served as Vice President of Clinical Development at Celgene where he was responsible for Phase 3 development of Abraxane for pancreatic, lung and metastatic breast cancer. He has also held senior level medical roles at Bionomics, Biothera, and Apobiologix where he oversaw the global clinical development of its oncology biosimilars program. He is widely conversant with regulatory bodies worldwide, government reimbursement agencies, oncology cooperatives and patient advocacy groups. He has extensively published in the oncology literature with over 8,000 citations. Dr. Iglesias graduated from medical school in 1986, spent 2 years as a fellow at Duke University and 2 years in oncology clinics and in private oncology and hematology practice prior to joining the pharmaceutical industry. 

Jose Iglesias Md

José Iglesias, MD

Chief Medical Officer

 

James Costin, MD

Head, Research & Development

Dr. James Costin has an extensive career in drug development in the pharmaceutical industry and is an interventional cardiologist by training. He completed his MD at Emory University School of Medicine and his house officer training at Yale University School of Medicine consisting of internship, residency, cardiology fellowship. Thereafter, he joined the cardiology section’s academic staff at Yale where he was primarily involved with the cardiac catherization laboratory and research. Following his position at Yale, he joined ICI’s pharmaceutical division where he was involved with all phases of drug development with a focus on marketing and Phase 4 studies. Dr. Costin joined Carter-Wallace pharmaceutical company as Vice President of Medical Affairs, and quickly advanced to Vice President of Research and Development, and ultimately Corporate Vice President of Medical and Scientific Affairs and Chief Medical Officer. While at Carter Wallace, Dr Costin established a drug development partnership with Geistlich Pharma AG. Following Carter-Wallace’s sale, he was Vice President and Chief Medical Officer of a new company, Perosphere, Inc., where he directed the development of a drug in the anticoagulation field. For the past 6 years, Dr Costin has consulted again with Geistlich Pharma to head the research and development of GP-2250 program.

James Costin

James Costin, MD

Head, Research & Development

 

Hanns Moehler, PhD

Head, Pharmacology

LinkedIn

Hanns Möhler is Professor em. at the Swiss Federal Institute of Technology (ETH), Zurich and the University of Zurich, Switzerland. He has held a professorship in pharmacology in the Department of Chemistry and Applied Biosciences, ETH Zurich, as well as in the Medical Faculty of the University of Zurich, where he was director of the Institute of Pharmacology.

He was the first director of the Swiss National Center of Neuroscience Research and director of the Center of Experimental and Clinical Pharma Sciences at the University and the University Hospital of Zurich. Prior to his academic positions, Hanns Möhler was vice-director in the Research Department of Hoffmann-La Roche, Basle, Switzerland.

His discovery of the benzodiazepine receptor and his work on sleep disorders, the regulation of anxiety states, the gene therapy of epilepsy and the neuronal organization of memory was honored by numerous awards. In recent years, his work has been focused on cancer therapy. He is a member of the Swiss Academy of Medical Sciences and the European Academy of Sciences.

Hanns Mohler

Hanns Moehler, PhD

Head, Pharmacology

 

Thomas Mueller, PhD

Head, Drug Substance & Product Development & API Manufacturing

LinkedIn

Dr. Thomas Mueller has over 25 years of experience in the pharmaceutical and medical device industry, most recently as director of pharmaceutical development Oncology and API production at Geistlich Pharma AG. He previously held a number of senior positions in the industry, including general manager of Konapharma AG, senior director business development and head chemical development at Siegfried Ltd. and CarboGen Amcis AG. Dr. Mueller’s operating responsibilities encompassed the development and commercialization of products in multiple therapeutic categories including oncology, neurologic, anti-infective, cardiovascular and psychiatric health areas. Dr. Mueller holds a Ph.D. degree in organic chemistry from the University of Constance, Germany, and concluded a postdoctoral fellowship at the Scripps Research Institute in San Diego California. He also earned CAS in Corporate Management at the Institute for Strategy and Business Economics of the University of Zuerich, Switzerland.

Thomas Muller

Thomas Mueller, PhD

Head, Drug Substance & Product Development & API Manufacturing

 

Ben Steinmetz

Chief Commercial Officer

LinkedIn

Ben Steinmetz comes to Panavance with a wealth of pharmaceutical launch experience and oncology expertise. Since 2018, he has been the Managing Director of the Steinmetz Advisory Group, specializing in the development and commercialization of oncology products. He serves as acting Chief Commercial Officer, as he is doing for Panavance, for pre-commercial stage oncology companies and is engaged with clients on projects ranging from development & commercial strategy for IND stage assets to market access strategy and execution for phase III and launch-stage products.

In 2015, Ben joined Churchill Pharmaceuticals as SVP Commercial, leading the launch of a new oral anticancer agent in a >$4 billion market. He established the product launch plan reflecting the competitive set, the differential timing of commercial and government payer reviews, the critical differences between physician dispensing and specialty pharmacy models, evolving US political and reimbursement environment, and the need to effectively deploy valuable human and monetary resources. Prior to Churchill, he was VP Reimbursement and Patient Access for GlaxoSmithKline and VP Policy and Payer Insight, Oncology/Biopharmaceuticals, in GSK’s US managed care division. Ben was VP Global Commercial Strategy, Oncology, and accountable for global product management, scientific communications, and health outcomes for GSK’s oncology portfolio. Product responsibilities included therapeutic and supportive care products such as Votrient®, Tykerb®, Arzerra®, Arranon®, and Promacta® as well as many discovery and development stage products. Before joining GSK, he worked in senior roles at Exocell, a development stage biotechnology company, and Eastman Pharmaceuticals/Sterling Winthrop (now Sanofi).

Ben Steinmetz

Ben Steinmetz

Chief Commercial Officer

 

Gary Gaglione, CPA 

Chief Financial Officer

Mr. Gaglione has extensive financial leadership experience across public and private biopharma start-ups as well as large pharmaceutical companies. Prior to joining Panavance, Mr. Gaglione was Chief Financial Officer and Vice President of Finance at Matinas Biopharma where he led and executed the Company’s financial strategies. Earlier, he served as Senior Director of Finance at Shionogi USA, Inc., and was responsible for budgeting and financial planning. He also served as Vice President of Finance and Controller for Phytomedics, Inc., a start-up botanical pharmaceutical company and was Controller for ProStrakan Inc.’s U.S. operations. Mr. Gaglione was also Executive Director at Reliant Pharmaceuticals, initially as Head of Planning, Budgets and Analysis, and then as Head of Internal Audit and Sarbanes Oxley Compliance in preparation for a potential initial public offering. Before Reliant, he held numerous finance positions of increasing responsibility at the U.S. subsidiary of Hoffmann-La Roche Inc, including Vice President of R&D Finance, Director of Compensation and Controller for the U.S. pharmaceutical division and sites. He started his finance career at KPMG LLP. Mr. Gaglione earned a B.S. degree in Business Administration with a major in Accounting from Villanova University, and an MBA in Finance from Seton Hall University.  

Gary Gaglione

Gary Gaglione, CPA 

Chief Financial Officer

 

Kathryn Martin, PharmaD

Head, Regulatory & Scientific Communications

LinkedIn

Dr. Kathryn (Kate) Martin is the President of Glenmere Research, a consulting firm located in Montebello, NY, that has been providing regulatory and medical editorial services to the pharmaceutical industry for more than 25 years. After receiving her BS from Northeastern University and PharmD from the University of Texas Health Science Center in San Antonio, Kate was the Director of Oncology Pharmacy Services for the Albert Einstein Cancer Center in the Bronx, NY. Her experience in the industry began at Lederle Laboratories in Pearl River, NY, in Medical Affairs and the Medical Research Division. Since founding Glenmere Research in 1995, Dr. Martin has provided regulatory and medical editorial services to large pharma and has assisted numerous small to mid-size companies with US, European, China, and Japan submissions. She has experience writing regulatory documents across the full product lifespan and is familiar with ICH guidelines, standardized templates, and electronic document management systems. Dr. Martin has written manuscripts that have been published in top tier journals including New England Journal of Medicine, Vaccine, Blood, and Contraception, as well as abstracts and posters at numerous domestic and international congresses including ASCO, ESMO, ACC, SABCS, and ASH. She has written content and developed internal medical education slide decks on topics including pathophysiology, therapeutic management, nonclinical and clinical data summaries, and competitive analysis. Her training and primary area of expertise is in oncology/hematology, including transplant and CAR-T therapy, and immunology.

Kathryn Martin

Kathryn Martin, PharmaD

Head, Regulatory & Scientific Communications

 

Duane Sofia, PhD

Head, Non-Clinical Research

Dr. Duane Sofia received his Ph.D. in Pharmacology from the University of Pittsburgh. He has over 45 years’ experience in the pharmaceutical industry as an active employee and more recently as a consultant. During his career Dr. Sofia has held increasingly responsible positions from Senior Research Pharmacologist to Director of Pharmacology and Toxicology and ultimately to Vice President of Preclinical Research. He has been intimately involved in the successful submission of a number of INDs, some of which led to NDA approval. He has been an active member of several professional societies including the American Society for Pharmacology and Experimental Therapeutics, the Society of Toxicology, and the American Epilepsy Society. He has authored or co-authored over 200 research articles in peer-reviewed journals dealing with the pharmacology, toxicology, drug metabolism and mechanism of action of experimental and newly developed drug therapies. In addition, he has authored or co-authored 11 book chapters. He also is the holder of 11 U.S. patents. Dr. Sofia has presented papers at numerous scientific meetings with abstracts totaling greater than 150.

Duane Sofia

Duane Sofia, PhD

Head, Non-Clinical Research

 

Robert Hrubiec, PhD, JD

Head, Intellectual Property & Patents

LinkedIn

Dr. Robert Hrubiec is an intellectual property attorney with over 25 years’ experience in all aspects of intellectual property, specializing in pharmaceutical, biotechnology and medical device/diagnostic patent management, strategic IP evaluation, litigation support, business development, mergers/acquisitions, licensing, FDA regulations, trademarks and patent preparation and prosecution. Dr. Hrubiec is currently the Consulting Intellectual Property Counsel for Panavance Therapeutics and is primarily responsible for providing general intellectual property consulting services, evaluating the company’s patents and patent applications, providing creative patent strategies to further protect key technologies and making intellectual property recommendations to upper management. Dr. Hrubiec is also the founder and President of Innoventiv IP, an intellectual property management and consulting company focused on advising high technology companies on legal matters, patent portfolio management, strategic planning, life-cycle management, licensing/acquisitions/confidentiality/clinical trial and other agreements, due diligence, maximizing value, cost reduction and litigation support. Prior to founding Innoventiv IP in 2012, Dr. Hrubiec was Vice President and Chief Intellectual Property Counsel at Cephalon, Inc., where he was responsible for creating, developing and managing the company’s global IP department as well as all IP aspects of business development. Prior to joining Cephalon in 1999, Dr. Hrubiec was an intellectual property attorney with GlaxoSmithKline and directed a research laboratory at Cytogen Corporation focused on cytotoxic agents conjugated to monoclonal antibodies for use in treating cancer. Dr. Hrubiec received his Ph.D. in synthetic organic chemistry from the University of Connecticut followed by a postdoctoral fellowship in pharmacology/molecular biology at the Yale Medical School Comprehensive Cancer Center. He obtained his law degree from the North Carolina Central University School of Law and is licensed in North Carolina, Pennsylvania and the USPTO.

Robert Hrubiec

Robert Hrubiec, PhD, JD

Head, Intellectual Property & Patents

 

William Vincek, PhD

Head, CMC & Quality

William Vincek is the founder of Pharma CMC Inc., which provides consulting to the pharmaceutical industry in the areas of regulatory affairs, quality assurance/control and CMC. His consulting skills draw from his 30+ years in pharmaceutical development: Merck, Sharp and Dohme, in human drug metabolism; SmithKline Beecham in dosage form development and analytical chemistry; Glaxo Welcome in quality assurance/control and regulatory affairs. He responsibilities included: SVP of development (CMC, clinical, & regulatory affairs) at Guilford Pharmaceuticals (Gliadel® wafer and LUSEDRA®); SVP of CMC, manufacturing, and distribution at MGI Pharma (Saforis™ and Amolimogene); and SVP of development and regulatory affairs at Alpharma Pharmaceuticals (EMBEDA® Extended-Release Capsules and Naltrexone Platform). Recently, he supported the development of a novel product with multiple actives using a combination of controlled release matrices and pH dependent enteric coatings compressed into a bilayer tablet. Currently, he is supporting the development of oral dosage forms from parenteral products. He has met with multiple divisions of the FDA both as the technical and regulatory expert. In addition, he filed an e-NDA for EMBEDA®, was the CMC presenter at a FDA Advisory Committee, and lead numerous CMC, quality, and regulatory due diligence teams.

William Vincek

William Vincek, PhD

Head, CMC & Quality